2020 - CARISMA Therapeutics

News & Events

August 25, 2020

CARISMA Therapeutics Enters Into Scientific Research and Licensing Agreement With NYU Langone Health, Gains Exclusive Rights to Vpx Lentiviral Vector

PHILADELPHIA, Aug. 25, 2020 /PRNewswire/ — CARISMA Therapeutics Inc., a biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced it has entered into a scientific research and licensing agreement with Nathaniel R. Landau, PhD and NYU Langone Health through which CARISMA will attain exclusive rights to develop and commercialize their Vpx lentiviral vector globally for all indications. […]

August 3, 2020

CARISMA Therapeutics to Participate in Upcoming Investor Conferences

PHILADELPHIA, July 30, 2020 /PRNewswire/ — CARISMA Therapeutics Inc., a biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced that the company will present at two virtual conferences in August 2020. Click here for more information.

July 27, 2020

CARISMA Therapeutics Announces FDA Clearance of IND Application for First-Ever Engineered Macrophage Immunotherapy

PHILADELPHIA, July 27, 2020 /PRNewswire/ — CARISMA Therapeutics Inc., a biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced that the U.S. Food and Drug Administration (FDA) has cleared an investigational new drug (IND) application for the Company’s lead product candidate, CT-0508, an anti-human epidermal growth factor receptor 2 (HER2) targeted chimeric antigen receptor macrophage (CAR-M). […]

May 21, 2020

Carisma Therapeutics to Present and Meet with Potential Investors at Upcoming Healthcare Investor Conferences

PHILADELPHIA, May 21, 2020 /PRNewswire/ — Carisma Therapeutics Inc., a biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced that the company will present and take meetings at upcoming virtual healthcare investor conferences in May and June 2020.Click here for more information.

May 15, 2020

New Data Uncover Potential of Expedited Pathway for Immunotherapy Development Through CAR Monocytes

Carisma Therapeutics expands on foundational first-of-its-kind engineered macrophage cell therapy platform study and explores time-reducing isolation-to-infusion pathway. For full press release, click here

March 23, 2020

First-of-its-kind Engineered Macrophage Cell Therapy Platform Shows Ability to Reduce Tumor Burden and Activate Anti-Tumor Immunity, Improving Overall Survival in Pre-Clinical Cancer Models

Study highlights previously untapped potential of genetically engineered macrophages in immunotherapy for solid tumors. For full press release, click here.

March 2, 2020

Carisma Therapeutics to Present at March Scientific and Investor Conferences

Carisma Therapeutics Inc., a biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced that the company will present at two conferences in March, 2020. For full press release, click here.

January 6, 2020

Carisma Therapeutics Expands Leadership Team

Carisma Therapeutics expands leadership with appointments of Debora Barton, MD as Chief Medical Officer, and Tom Wilton as Chief Business Officer. For full press release, see here.